Mr. Claypoole joins Bioventus from Mölnlycke Health Care, a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business and rapidly accelerated growth from mid-single digit to consistent double-digit growth in sales and profitability, while also advancing Mölnlycke’s evolution as an innovative wound care solutions company across the continuum of care – from prevention to treatment in acute and post-acute settings. Before that, Mr. Claypoole was Executive Vice President and President, US for Mölnlycke where he turned around a declining business to strong growth and served as an Officer of Mölnlycke Health Care US, LLC and Mölnlycke Manufacturing US, LLC. In this role, Rob was responsible for over $.5B in revenue.
Prior to joining Mölnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health and led the effort to address one of the most significant healthcare challenges. Previously, he served as Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business where he led a successful global turnaround from years of declining revenue to significant growth. Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company’s Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson’s Vision Care division.
Rob received his Bachelor’s degree and his Master’s degree in Business Administration from Cornell University.
What is Robert E. Claypoole's net worth?
The estimated net worth of Robert E. Claypoole is at least $559.99 thousand as of January 13th, 2025. Claypoole owns 64,964 shares of Bioventus stock worth more than $559,990 as of March 13th. This net worth estimate does not reflect any other assets that Claypoole may own. Learn More about Robert E. Claypoole's net worth.
How do I contact Robert E. Claypoole?
Has Robert E. Claypoole been buying or selling shares of Bioventus?
Robert E. Claypoole has not been actively trading shares of Bioventus within the last three months. Most recently, Robert E. Claypoole sold 28,786 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a transaction totalling $261,952.60. Following the completion of the sale, the chief executive officer now directly owns 64,964 shares of the company's stock, valued at $591,172.40. Learn More on Robert E. Claypoole's trading history.
Who are Bioventus' active insiders?
Are insiders buying or selling shares of Bioventus?
During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company.
Learn More about insider trades at Bioventus. Information on this page was last updated on 3/11/2026.
